Medidata, a global leader in clinical trial technology, has launched Medidata Plus, an AI-native foundation designed to bring scalable intelligence across clinical research portfolios and accelerate the development of life-saving therapies.
Built on Medidata’s award-winning artificial intelligence infrastructure, Medidata Plus aims to break down the industry’s reliance on fragmented AI tools by delivering a unified, end-to-end AI strategy across the clinical trial lifecycle.
The platform enables sponsors and contract research organizations (CROs) to apply AI-driven insights consistently across global portfolios — from study design and data management to risk monitoring and regulatory readiness.
The launch comes as life sciences organizations rapidly increase AI investments but struggle to achieve expected returns. While 92% of industry decision-makers plan to expand AI spending, only 29% say current AI capabilities meet or exceed expectations.
Medidata Plus is designed to address those challenges by creating a standardized AI layer that improves efficiency, reduces complexity, and turns AI adoption into a predictable enterprise capability.
"Stitching together point solutions isn't a strategy — it's a liability. Drug development's next leap will come when AI is consistent, connected, and portfolio-wide," said Nimita Limaye, Research VP, Life Sciences R&D Strategy and Technology, IDC.
"Medidata Plus delivers this with a cohesive AI layer across the entire lifecycle, shifting organizations from sporadic AI adoption to a continuous, portfolio-wide strategy that drives real clinical outcomes.”
“We've listened to our customers and they're clear that AI can transform clinical trials, but not as an army of agents from disparate sources trained in disparate ways," said Anthony Costello, CEO, Medidata.
"Medidata Plus is a drop-in AI strategy for clinical research that upskills teams, automates workflows, and surfaces insights at a pace that's redefining what teams thought was possible. We are in conversations with dozens of customers about making this shift and what we're hearing tells us the industry has been waiting for exactly this.”
The company said Medidata Plus will provide enterprise biopharma companies and global CROs with a competitive advantage by improving trial precision, increasing quality, and shortening development timelines.
